Hiroshi Nakamura1, Shigehiro Tamaki2, Takahiro Yagyuu2, Nobuhiro Yamakawa2, Katsuhiko Hatake3, Tadaaki Kirita2. 1. Department of Oral and Maxillofacial Surgery, Nara Medical University, Nara, Japan nakahiro@naramed-u.ac.jp. 2. Department of Oral and Maxillofacial Surgery, Nara Medical University, Nara, Japan. 3. Department of Legal Medicine, Nara Medical University, Nara, Japan.
Abstract
BACKGROUND/AIM: Cetuximab treatment targets the epidermal growth factor receptor (EGFR) overexpressed in oral cancer. This study aimed to investigate the anti-tumour activity of cetuximab against oral cancer cell lines with respect to antibody-dependent cell-mediated cytotoxicity (ADCC), and determine the correlation between ADCC and EGFR expression. MATERIALS AND METHODS: EGFR expression in oral cancer cells was measured by quantitative flow cytometric analysis and immunohistochemistry. ADCC activity was measured by 4-h calcein release assays. RESULTS: Cetuximab-mediated ADCC against oral cancer cells was detectable at a concentration of 0.1 μg/ml. A high correlation was observed between the number of EGFR molecules on the surface of oral cancer cells and ADCC (correlation coefficient: 0.847; p=0.032). CONCLUSION: ADCC is an important mechanism underlying the therapeutic effect of cetuximab, and EGFR expression in tumour cells might serve as a predictive marker to evaluate the effect of cetuximab treatment. Copyright
BACKGROUND/AIM: Cetuximab treatment targets the epidermal growth factor receptor (EGFR) overexpressed in oral cancer. This study aimed to investigate the anti-tumour activity of cetuximab against oral cancer cell lines with respect to antibody-dependent cell-mediated cytotoxicity (ADCC), and determine the correlation between ADCC and EGFR expression. MATERIALS AND METHODS:EGFR expression in oral cancer cells was measured by quantitative flow cytometric analysis and immunohistochemistry. ADCC activity was measured by 4-h calcein release assays. RESULTS:Cetuximab-mediated ADCC against oral cancer cells was detectable at a concentration of 0.1 μg/ml. A high correlation was observed between the number of EGFR molecules on the surface of oral cancer cells and ADCC (correlation coefficient: 0.847; p=0.032). CONCLUSION: ADCC is an important mechanism underlying the therapeutic effect of cetuximab, and EGFR expression in tumour cells might serve as a predictive marker to evaluate the effect of cetuximab treatment. Copyright
Authors: Hasan Baysal; Ines De Pauw; Hannah Zaryouh; Marc Peeters; Jan Baptist Vermorken; Filip Lardon; Jorrit De Waele; An Wouters Journal: Front Immunol Date: 2021-09-07 Impact factor: 7.561
Authors: Julie Jacobs; An Wouters; Hasan Baysal; Ines De Pauw; Hannah Zaryouh; Jorrit De Waele; Marc Peeters; Patrick Pauwels; Jan Baptist Vermorken; Evelien Smits; Filip Lardon Journal: Br J Cancer Date: 2020-06-16 Impact factor: 7.640